{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:48:37Z","timestamp":1783475317127,"version":"3.55.0"},"reference-count":0,"publisher":"Ideggyogyaszati Szemle Journal","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ideggy\u00f3gy\u00e1szati szemle"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background and purpose \u2013 Flunarizine is a\nspecific calcium antagonist and is frequently\nused in adults for the prophylactic treatment\nof migraine. The use of flunarizine may lead\nto somnolence and weight gain, depression, and rarely extrapyramidal symptoms\nin adults. However, studies detecting the\nefficacy and safety of flunarizine use in adolescents are limited. In the current study, the\neffectiveness of flunarizine for the management of migraine without aura in Turkish\nadolescents was evaluated.\nMethods \u2013 Forty-six patients with migraine\nwithout aura, receiving flunarizine 5mg per\nday were included. In this retrospective\nstudy, the medical records of the cases were\nexamined. Visual Analog Scale (VAS) and\nMIDAS scores were compared to assess the\nefficacy of the 3 months treatment.\nResults \u2013 The mean age was 14.37\u00b11.83\nyears. There was a significant improvement\nin the VAS and MIDAS scores of the patients\nat the end of the third month (p&lt;0.05).\nSide effects were detected in 23.9% of the\npatients, and these symptoms were sedation\nin 8.7% of the patients, mood swings in 4.3%,\nand vomiting in 4.3% of them. None of the\npatients discontinued the treatment due to\nside effects.\nConclusion \u2013 Although the advancement of\nmigraine research and treatment is inevitable, our findings support that flunarizine\nshould still be considered as an effective and\ntolerable treatment option in adolescent\nmigraineurs.<\/jats:p>","DOI":"10.18071\/isz.77.0122","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:06:50Z","timestamp":1743156410000},"page":"122-126","source":"Crossref","is-referenced-by-count":2,"title":["Management of migraine without aura in adolescents: The experience of flunarizine use in a Turkish cohort"],"prefix":"10.18071","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-1653","authenticated-orcid":false,"given":"Faik","family":"Ilik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5309-1258","authenticated-orcid":false,"given":"Devrimsel Harika","family":"Ertem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-5415","authenticated-orcid":false,"given":"M. Kemal","family":"Ilik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7411","published-online":{"date-parts":[[2025]]},"container-title":["Ideggy\u00f3gy\u00e1szati szemle"],"original-title":[],"link":[{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/management-of-migraine-without-aura-in-adolescents-the-experience-of-flunarizine-use-in-a-turkish-cohort\/pdf-open","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:06:55Z","timestamp":1743156415000},"score":1,"resource":{"primary":{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/management-of-migraine-without-aura-in-adolescents-the-experience-of-flunarizine-use-in-a-turkish-cohort"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.18071\/isz.77.0122","relation":{},"ISSN":["0019-1442","2498-6208"],"issn-type":[{"value":"0019-1442","type":"print"},{"value":"2498-6208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}